The reduction of bone mineral density in postmenopausal women with primary hyperparathyroidism is higher in the presence of concomitant GH secretion impairment

European Journal of Endocrinology

Volumn 155, Issue 1, 2006, Pages 41-45

  Cecconi, Elisabetta ^c   Gasperi, Maurizio ^c   Genovesi, Maura ^c   Bogazzi, Fausto ^c   Grasso, Lucia ^c   Cetani, Filomena ^c   Procopio, Massimo ^a   Marcocci, Claudio ^a   Bartalena, Luigi ^b   Martino, Enio ^c  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF INSUBRIA   (Italy)

^c UNIVERSITY OF PISA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; CALCIUM ION; GROWTH HORMONE; GROWTH HORMONE RELEASING FACTOR; PARATHYROID HORMONE; SOMATOMEDIN C;

ADULT; AGED; ARTICLE; BODY MASS; BONE DEFECT; BONE DENSITY; BONE MASS; BONE METABOLISM; BONE REMODELING; CALCIUM BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SEVERITY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FEMUR NECK; GROWTH HORMONE DEFICIENCY; GROWTH HORMONE RELEASE; HORMONE RESPONSE; HUMAN; MENOPAUSE; OSTEOPENIA; OSTEOPOROSIS; PATHOGENESIS; POSTMENOPAUSE; PRIMARY HYPERPARATHYROIDISM; PRIORITY JOURNAL; SCORING SYSTEM;

AGED; AGED, 80 AND OVER; BODY MASS INDEX; BONE DENSITY; BONE REMODELING; DENSITOMETRY, X-RAY; FEMALE; GROWTH HORMONE-RELEASING HORMONE; HUMAN GROWTH HORMONE; HUMANS; HYPERPARATHYROIDISM; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PARATHYROID HORMONE; POSTMENOPAUSE;

EID: 33746296610     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.1.02181     Document Type: Article

References (23)

1. Silverberg SJ & Bilezikian JP. Clinical presentation of primary hyperparathyroidism in the United States. In The Parathyroids: Basic and Clinical Concepts. 2nd edn, pp. 349-360, New York: Academic Press, 2001.
2. Silverberg SJ & Bilezikian JP. Clinical course of primary hyperparathyroidism in the United States. In The Parathyroids: Basic and Clinical Concepts. 2nd edn, pp. 387-398, New York: Academic Press, 2001.
3. Silverberg SJ. Natural history of primary hyperparathyroidism. Endocrinology Metabolism Clinics of North America 2000 29 451-464.
4. Seibel MJ. Molecular markers of bone metabolism in parathyroid disease. In The Parathyroids: Basic and Clinical Concepts. 2nd edn, pp. 399-409, New York: Academic Press, 2001.
5. Gasperi M, Cecconi E, Grasso L, Bartalena L, Centoni R, Aimaretti G, Broglio F, Miccoli P, Marcocci C, Ghigo E & Martino E. GH secretion is impaired in patients with primary hyperparathyroidism. Journal of Clinical Endocrinology and Metabolism 2002 87 1961-1964.
6. Cecconi E, Gasperi M, Grasso L, Genovesi M, Amaretti G, Broglio F, Bartalena L, Marcocci C & Martino E. Primary hyperparathyroidism is associated with an impaired secretion of growth hormone but not of the other anterior pituitary hormones. Journal of Endocrinological Investigation 2002 25 RC7-RC9.
7. Cecconi E, Gasperi M, Bogazzi F, Grasso L, Genovesi M, Marcocci C, Pinchera A, Procopio M, Bartalena L & Martino E. Improvement of growth hormone deficiency in patients with primary hyperparathyroidism after parathyroidectomy: results of a prospective study. Journal of Clinical Endocrinology and Metabolism 2004 89 1213-1216.
8. Cecconi E, Bogazzi F, Cetani F, Grasso L, Marcocci C, Genovesi M, Procopio M, Gasperi M, Pinchera A, Ghigo E & Martino E. Impaired GH secretion to provocative stimuli in two families with hypocalciuric hypercalcaemia. Clinical Endocrinology 2003 59 604-606.
9. Cecconi E, Gasperi M, Genovesi M, Bogazzi F, Grasso L, Procopio M, Marcocci C, Pinchera A, Bartalena L & Martino E. Growth hormone secretion in primary and secondary hyperparathyroidism. Journal of Endocrinological Investigation 2005 28 113-116.
10. Ohlsson C, Bengtsson B, Isaksson OGP, Andreassen TT & Slootweg MC. Growth hormone and bone. Endocrine Reviews 1998 19 55-79.
11. Doga M, Bonadonna S, Gola M, Mazziotti G, Nuzzo M & Giustina A. GH deficiency in the adult and bone. Journal of Endocrinological Investigation 2005 28 18-23.
12. Wuster C, Bengtsson B, Bennmarker H, Feldt-Rasmussen U, Hernberg-Stahl E, Monson JP, Westberg B, Wilton P and on behalf of the kims study group and the kims international board. The influence of growth hormone deficiency, growth hormone replacement therapy and other aspect of hypopituitarism on fracture rate and bone mineral density. Journal of Bone and Mineral Research 2001 16 398-405.
13. Aimaretti G, Corneli G, Razzore P, Bellone S, Baffoni C, Arvat E & Ghigo E. Comparison between insulin-induced hypoglycemia and Growth Hormone (GH)-Releasing Hormone + Arginine provocative tests for the diagnosis of GH deficiency adults. Journal of Clinical Endocrinology and Metabolism 1998 83 1615-1624.
14. Valetto MR, Bellone J & Baffoni C. Reproducibility of the growth hormone response to stimulation with growth hormone-releasing hormone plus arginine during lifespan. European Journal Endocrinology 1986 135 568-572.
15. Cormier C, Souberbielle JC & Kahan A. Primary hyperparathyroidism and osteoporosis in 2004. Joint Bone Spine 2004 71 183-189.
16. Thor Ueland. Bone metabolism in relation to alterations in systemic growth hormone. Growth Hormone and IGF Research 2004 14 404-417.
17. Thor Ueland. GH/IGF-I and bone resorption in vivo and in vitro. European Journal of Endocrinology 2005 152 327-332.
18. Colao A, Di Somma C, Pivonello R, Loche S, Aimaretti G, Cerbone G, Faggiano A, Corneli G, Ghigo E & Lombardi G. Bone loss is correlated to the severity of growth hormone deficiency in adult patients with hypopituitarism. Journal of Clinical Endocrinology and Metabolism 1999 84 1919-1924.
19. Biermasz NR, Neveen A, Hamdy NAT, Pereira AM, Romijn JA & Roelfsema F. Long-term skeletal effects of recombinant human growth hormone (rhGH) alone and rhGH combined with alendronate in GH-deficients adults: a seven-year follow-up study. Clinical Endocrinology 2004 60 568-575.
20. Seibel MJ. Biochemical markers of bone metabolism in the assessment of osteoporosis: Useful or not? Journal of Endocrinological Investigation 2003 26 464-471.
21. Stepan JJ. Clinical utility of bone markers in the evaluation and follow-up of osteoporotic patients: Why are the markers poorly accepted by clinicians? Journal of Endocrinological Investigation 2003 6 458-463.
22. Rodriguez-Arnao J, James I, Jabbar A, Trainer PJ, Perrett D, Besser GM & Ross J. Serum collagen cross links as markers of bone turnover during GH replacement therapy in growth hormone deficient adults. Clinical Endocrinology 1998 48 455-462.
23. Delmas PD. Markers of bone turnover for monitoring treatment of osteoporosis with antiresorptive drugs. Osteoporosis International 2000 6 566-576.